Article
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Lung cancer (Amsterdam, Netherlands) - 1 Mar 2025
Morimoto Kenji, Yamada Tadaaki, Furuya Naoki, Tanaka Hisashi, Yoshimura Akihiro, Oba Tomohiro, Hibino Makoto, Fukuda Takahito, Goto Yasuhiro, Nakao Akira, Ogusu Shinsuke, Okazaki Yuta, Harada Taishi, Ota Takayo, Masubuchi Ken, Mikami Koji, Hata Tae, Matsumoto Shoki, Honda Ryoichi, Date Koji, Chihara Yusuke, Takayama Koichi
Abstract excerpt
OBJECTIVES: In patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, a chemoimmunotherapy regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) has shown promising outcomes following treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, evidence on whether ABCP provides a survival advantage over platinum-based chemotherapy...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Non-Small-Cell Lung
- Female